SCHEMBL4060436

SCHEMBL4060436

N#Cc1ccc2c(c1)CNCN2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 7/20 0.54
DRD2 P14416 3/20 0.54
DRD3 P35462 3/20 0.54
CHRNA1 P02708 1/20 0.37
CHRNG P07510 1/20 0.37
CHRNB1 P11230 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
CHRND Q07001 1/20 0.37
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
HTR2B P41595 2/20 0.34
CYP19A1 P11511 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
IMPDH2 P12268 1/20 0.33
IMPDH1 P20839 1/20 0.33
SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30294431 0.86 PNMT (0.54) PNMTDRD2DRD3CHRNA1CHRNG
SCHEMBL288540 0.76 DRD2 (0.55) PNMTDRD2DRD3CYP19A1CYP11B1
SCHEMBL20756641 0.75 DRD2 (0.40) PNMTDRD2DRD3CHRNA1CHRNG
SCHEMBL330686 0.75 PNMT (0.75) PNMTDRD2DRD3CHRNA1CHRNG
SCHEMBL31403008 0.75 PNMT (0.75) PNMTDRD2DRD3CHRNA1CHRNG
Hydrochloric Acid SCHEMBL4276399 0.74 DRD2 (0.53) PNMTDRD2DRD3CYP19A1CYP11B1
SCHEMBL19512772 0.74 PNMT (0.49) PNMTDRD2DRD3CHRNA1CHRNG
Hydrochloric Acid SCHEMBL21800263 0.73 PNMT (0.72) PNMTDRD2DRD3CHRNA1CHRNG
SCHEMBL3116370 0.73 MAPT (0.51) PNMTDRD2DRD3CYP19A1CYP11B1
SCHEMBL29659943 0.73 MAPT (0.51) PNMTDRD2DRD3CYP19A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648250-B2 Tetrahydroquinazoline derivatives as selective cytotoxic agents MERCK SHARP & DOHME LLC (US) 2023-05-16 US claimed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 EP disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed
WO-2009115874-A2 NOVEL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION MATRIX LABORATORIES LTD. (IN) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648250-B2 Tetrahydroquinazoline derivatives as selective cytotoxic agents ACIN1, REV1, NFATC1 PNMT 2611/4885DRD2 2472/4885DRD3 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.